← Back to screener

Kymera Therapeutics, Inc. KYMR

Rank #2343 · Nasdaq · $10.4B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
23.4
P/E
-70.9
P/B
21.25
ROE
-30.0%
Op. Margin
-210.6%
Debt Ratio
29%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -70.9x, P/B 21.25x. Ranks in the top 80% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -30.0%. Ranks in the top 88% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 29%. Ranks in the top 16% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 67.8% year over year. Ranks in the top 5% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020$0.0B$-0.0B$-0.0B$-0.0B-1438.5-238
2021$0.0B$-0.0B$-0.0B$-0.0B-1438.5-590
2022$0.0B$-0.0B$-0.0B$-0.1B-136.1-197
2023$0.1B$-0.1B$-0.1B$0.3B-138.040
2024$0.0B$-0.2B$-0.2B$0.5B-344.439
2025$0.1B$-0.2B$-0.1B$0.5B-210.629

← See the full screener